{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "claude-opus-4-5",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective - Symptomatic Response Evaluation",
        "text": "To evaluate patients' symptomatic responses following diagnosis and treatment based on the results of the molecular method versus those from the conventional urine culture method",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Antibiotic Selection Efficacy",
        "text": "To determine the efficacy of antibiotic selection using molecular method versus the conventional urine culture method",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - Clinical Utility Assessment",
        "text": "To assess clinical utility of Polymerase Chain Reaction (PCR) results during the clinical decision-making phase in patient care",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Antimicrobial Susceptibility Availability",
        "text": "To compare the availability of the antimicrobial susceptibility information from molecular testing and conventional testing at the time of initial antimicrobial therapy",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Diagnostic Agreeability",
        "text": "To quantify the overall agreeability between the diagnostic results generated by PCR versus Culture and Sensitivity (C&S)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Discordant Results Assessment",
        "text": "To assess the symptomatic responses of patients with discordant results [PCR(+), CS(-) and PCR(-), CS(+)]",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Objective - Clinically Insignificant Infection Detection",
        "text": "To assess the effectiveness of PCR in avoiding detection of clinically insignificant infections in comparison to the performance of C&S",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint - Favorable Clinical Outcomes",
        "text": "Number (and percentage) of patients in each study arm with favorable clinical outcomes at the EOS visit. Favorable clinical outcomes are defined as a clinical response of improvement and/or cure. Clinical improvement is defined as 1) Resolution of cUTI signs and symptoms present at baseline, 2) Development of no new cUTI symptoms and/or 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization. Clinical cure is resolution of all acute signs and symptoms of cUTI and improvement to such an extent that no further antimicrobial therapy (IV or oral) is required for the treatment of the cUTI",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Endpoint - Microbiological Eradication",
        "text": "Number (and percentage) of patients in each arm with microbiological eradication of all baseline pathogens at the EOS visit. Microbiological eradication of all baseline pathogens is defined as an end of study quantitative urine culture that shows all uropathogens found at baseline are reduced to <105 CFU/mL and all baseline pathogens are not detected by EOS urine PCR (Cq>33)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Endpoint - Treating Investigator Satisfaction Score",
        "text": "Subjective measurement of Treating Investigator Satisfaction Score as evaluated by the questionnaire at EOS",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint - Turnaround Time",
        "text": "Turnaround Time (as measured in hours) of molecular diagnostic procedures compared to conventional diagnostics (time from collection of samples to complete identification of organism(s) and availability of antimicrobial susceptibility results)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint - Diagnostic Agreeability",
        "text": "Overall agreeability between the diagnostic results generated by PCR versus C&S as assessed by discordant analysis",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - Discordant Results Clinical Outcomes",
        "text": "Assess the favorable clinical outcomes of patients with discordant results [PCR(+), CS(-) and PCR(-), CS(+)]",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint - Negative Percent Agreement",
        "text": "The negative percent agreement of the PCR test (specificity) compared to C&S in not detecting clinically insignificant UTIs",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Safety Endpoint - Clinical Observations",
        "text": "Clinical observations",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Safety Endpoint - Vital Sign Measurements",
        "text": "Vital sign measurements",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Safety Endpoint - Laboratory Tests",
        "text": "Laboratory tests",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Safety Endpoint - Reported Adverse Events",
        "text": "Reported adverse events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "Safety Endpoint - Treatment Emergent Adverse Events",
        "text": "Assessment of Treatment Emergent Adverse Events (TEAE) at EOS",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 5,
      "exploratoryObjectives": 1,
      "totalEndpoints": 12,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective - Symptomatic Response Evaluation",
        "text": "To evaluate patients' symptomatic responses following diagnosis and treatment based on the results of the molecular method versus those from the conventional urine culture method",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Antibiotic Selection Efficacy",
        "text": "To determine the efficacy of antibiotic selection using molecular method versus the conventional urine culture method",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - Clinical Utility Assessment",
        "text": "To assess clinical utility of Polymerase Chain Reaction (PCR) results during the clinical decision-making phase in patient care",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Antimicrobial Susceptibility Availability",
        "text": "To compare the availability of the antimicrobial susceptibility information from molecular testing and conventional testing at the time of initial antimicrobial therapy",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Diagnostic Agreeability",
        "text": "To quantify the overall agreeability between the diagnostic results generated by PCR versus Culture and Sensitivity (C&S)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Discordant Results Assessment",
        "text": "To assess the symptomatic responses of patients with discordant results [PCR(+), CS(-) and PCR(-), CS(+)]",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Objective - Clinically Insignificant Infection Detection",
        "text": "To assess the effectiveness of PCR in avoiding detection of clinically insignificant infections in comparison to the performance of C&S",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint - Favorable Clinical Outcomes",
        "text": "Number (and percentage) of patients in each study arm with favorable clinical outcomes at the EOS visit. Favorable clinical outcomes are defined as a clinical response of improvement and/or cure. Clinical improvement is defined as 1) Resolution of cUTI signs and symptoms present at baseline, 2) Development of no new cUTI symptoms and/or 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization. Clinical cure is resolution of all acute signs and symptoms of cUTI and improvement to such an extent that no further antimicrobial therapy (IV or oral) is required for the treatment of the cUTI",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Secondary Endpoint - Microbiological Eradication",
        "text": "Number (and percentage) of patients in each arm with microbiological eradication of all baseline pathogens at the EOS visit. Microbiological eradication of all baseline pathogens is defined as an end of study quantitative urine culture that shows all uropathogens found at baseline are reduced to <105 CFU/mL and all baseline pathogens are not detected by EOS urine PCR (Cq>33)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Secondary Endpoint - Treating Investigator Satisfaction Score",
        "text": "Subjective measurement of Treating Investigator Satisfaction Score as evaluated by the questionnaire at EOS",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint - Turnaround Time",
        "text": "Turnaround Time (as measured in hours) of molecular diagnostic procedures compared to conventional diagnostics (time from collection of samples to complete identification of organism(s) and availability of antimicrobial susceptibility results)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint - Diagnostic Agreeability",
        "text": "Overall agreeability between the diagnostic results generated by PCR versus C&S as assessed by discordant analysis",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - Discordant Results Clinical Outcomes",
        "text": "Assess the favorable clinical outcomes of patients with discordant results [PCR(+), CS(-) and PCR(-), CS(+)]",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint - Negative Percent Agreement",
        "text": "The negative percent agreement of the PCR test (specificity) compared to C&S in not detecting clinically insignificant UTIs",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "Safety Endpoint - Clinical Observations",
        "text": "Clinical observations",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "name": "Safety Endpoint - Vital Sign Measurements",
        "text": "Vital sign measurements",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_10",
        "name": "Safety Endpoint - Laboratory Tests",
        "text": "Laboratory tests",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_11",
        "name": "Safety Endpoint - Reported Adverse Events",
        "text": "Reported adverse events",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_12",
        "name": "Safety Endpoint - Treatment Emergent Adverse Events",
        "text": "Assessment of Treatment Emergent Adverse Events (TEAE) at EOS",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}